Domperidone

Domperidone Tablets (10mg) and Suspension (5mg/5ml) is a peripheral dopamine D2 receptor antagonist antiemetic and prokinetic on the WHO Model List framework. Because it does not readily cross the blood-brain barrier, it acts primarily at the chemoreceptor trigger zone (outside the blood-brain barrier) and gastrointestinal tract, stimulating upper GI motility, increasing LES pressure, and accelerating gastric emptying. Indicated for relief of symptoms of nausea and vomiting of various etiologies, and diabetic gastroparesis.

Domperidone Tablets (10mg) and Suspension (5mg/5ml) is a peripheral dopamine D2 receptor antagonist antiemetic and prokinetic on the WHO Model List framework. Because it does not readily cross the blood-brain barrier, it acts primarily at the chemoreceptor trigger zone (outside the blood-brain barrier) and gastrointestinal tract, stimulating upper GI motility, increasing LES pressure, and accelerating gastric emptying. Indicated for relief of symptoms of nausea and vomiting of various etiologies, and diabetic gastroparesis.

Omeprazole (20mg gastro-resistant) and Domperidone (10mg/30mg sustained-release) is a cornerstone fixed-dose PPI and prokinetic combination on the WHO Model List framework. Omeprazole irreversibly suppresses gastric acid secretion by inhibiting parietal cell H+/K+-ATPase. Domperidone blocks peripheral dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, stimulating gastric motility and preventing acid reflux. Indicated for gastroesophageal reflux disease, non-ulcer dyspepsia, and peptic ulcer disease accompanied by nausea, fullness, or vomiting.

Rabeprazole Sodium (20mg enteric-coated) and Domperidone (10mg/30mg sustained-release) is a rapid-onset PPI and prokinetic combination. Rabeprazole has a higher pKa (~5.0) than other PPIs, allowing faster activation at higher pH and achieving rapid, potent inhibition of gastric H+/K+-ATPase pumps from the first dose. Domperidone provides dopamine D2 antagonism to enhance lower esophageal sphincter tone and accelerate gastric emptying. Indicated for erosive esophagitis, GERD, hypersecretory conditions, and dyspeptic symptom complexes (nausea, postprandial fullness, acid regurgitation).

Pantoprazole (20mg/40mg enteric-coated) and Domperidone (10mg/30mg sustained/prolonged-release) is a fixed-dose combination antiulcer and prokinetic therapy. Pantoprazole irreversibly binds to the gastric H+/K+-ATPase proton pump on parietal cells, suppressing basal and stimulated hydrochloric acid secretion for >24 hours. Domperidone is a peripheral dopamine D2 receptor antagonist that accelerates gastric emptying and increases lower esophageal sphincter (LES) tone without crossing the blood-brain barrier. Indicated for gastroesophageal reflux disease (GERD) with reflux esophagitis, non-ulcer dyspepsia, diabetic gastroparesis, and acid peptic disorders associated with nausea, fullness, or early satiety.

Esomeprazole (40mg enteric-coated) and Domperidone (30mg sustained-release) combines the pure S-enantiomer of omeprazole with an antiemetic prokinetic. Esomeprazole provides superior bioavailability and acid suppression compared to racemic omeprazole by undergoing lower first-pass hepatic metabolism via CYP2C19. Domperidone provides dopamine D2 receptor antagonism, enhancing lower esophageal sphincter tone and gastroduodenal transit. Indicated for erosive reflux esophagitis, GERD poorly responsive to standard acid suppression, and diabetic gastroparesis with nausea.

Rabeprazole Sodium (20mg enteric-coated) and Domperidone (10mg/30mg sustained-release) is a rapid-onset PPI and prokinetic combination. Rabeprazole has a higher pKa (~5.0) than other PPIs, allowing faster activation at higher pH and achieving rapid, potent inhibition of gastric H+/K+-ATPase pumps from the first dose. Domperidone provides dopamine D2 antagonism to enhance lower esophageal sphincter tone and accelerate gastric emptying. Indicated for erosive esophagitis, GERD, hypersecretory conditions, and dyspeptic symptom complexes (nausea, postprandial fullness, acid regurgitation).

Ranitidine (150mg) and Domperidone (10mg) Tablets combines an H2-receptor antagonist with a peripheral prokinetic dopamine antagonist. Ranitidine reduces gastric acid volume and acidity, while domperidone accelerates gastric emptying and reinforces lower esophageal sphincter tone. Indicated for GERD, dyspepsia, hyperacidity, and heartburn accompanied by nausea or gastric stasis.

Naproxen (250mg/500mg) and Domperidone (10mg) Tablets is a migraine and arthritic combination. Naproxen eliminates pain and neurogenic inflammation; domperidone accelerates gastric emptying through peripheral dopamine D2 antagonism, reversing migraine-induced gastric stasis and relieving migraine nausea. Indicated for acute migraine attacks and arthritic pain with gastric fullness.

Naproxen (250mg/500mg) and Domperidone (10mg) Tablets is a migraine and arthritic combination. Naproxen eliminates pain and neurogenic inflammation; domperidone accelerates gastric emptying through peripheral dopamine D2 antagonism, reversing migraine-induced gastric stasis and relieving migraine nausea. Indicated for acute migraine attacks and arthritic pain with gastric fullness.

Omeprazole (20mg gastro-resistant) and Domperidone (10mg/30mg sustained-release) is a cornerstone fixed-dose PPI and prokinetic combination on the WHO Model List framework. Omeprazole irreversibly suppresses gastric acid secretion by inhibiting parietal cell H+/K+-ATPase. Domperidone blocks peripheral dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, stimulating gastric motility and preventing acid reflux. Indicated for gastroesophageal reflux disease, non-ulcer dyspepsia, and peptic ulcer disease accompanied by nausea, fullness, or vomiting.

Pantoprazole (20mg/40mg enteric-coated) and Domperidone (10mg/30mg sustained/prolonged-release) is a fixed-dose combination antiulcer and prokinetic therapy. Pantoprazole irreversibly binds to the gastric H+/K+-ATPase proton pump on parietal cells, suppressing basal and stimulated hydrochloric acid secretion for >24 hours. Domperidone is a peripheral dopamine D2 receptor antagonist that accelerates gastric emptying and increases lower esophageal sphincter (LES) tone without crossing the blood-brain barrier. Indicated for gastroesophageal reflux disease (GERD) with reflux esophagitis, non-ulcer dyspepsia, diabetic gastroparesis, and acid peptic disorders associated with nausea, fullness, or early satiety.

Domperidone (10mg) and Paracetamol (325mg) Tablets is a fixed-dose antiemetic and analgesic-antipyretic combination. Paracetamol provides centrally mediated analgesia and antipyresis via prostaglandin synthesis inhibition, while domperidone accelerates gastric emptying through peripheral dopamine D2 antagonism, counteracting migraine-induced gastric stasis and enhancing the absorption and therapeutic onset of paracetamol. Indicated for acute relief of headache, migraine attacks accompanied by nausea or vomiting, and febrile conditions with gastric fullness.

Cinnarizine (20mg) and Domperidone (15mg) Tablets is a dual-action vestibular sedative and antiemetic combination. Cinnarizine acts as a selective T-type voltage-gated calcium channel blocker and H1-antihistamine, suppressing labyrinthine overstimulation in the inner ear. Domperidone blocks peripheral dopamine D2 receptors in the CTZ, preventing motion-induced and labyrinthine nausea. Indicated for vertigo, motion sickness, Meniere's disease, and peripheral vestibular disorders accompanied by nausea and vomiting.

Pantoprazole (20mg/40mg enteric-coated) and Domperidone (10mg/30mg sustained/prolonged-release) is a fixed-dose combination antiulcer and prokinetic therapy. Pantoprazole irreversibly binds to the gastric H+/K+-ATPase proton pump on parietal cells, suppressing basal and stimulated hydrochloric acid secretion for >24 hours. Domperidone is a peripheral dopamine D2 receptor antagonist that accelerates gastric emptying and increases lower esophageal sphincter (LES) tone without crossing the blood-brain barrier. Indicated for gastroesophageal reflux disease (GERD) with reflux esophagitis, non-ulcer dyspepsia, diabetic gastroparesis, and acid peptic disorders associated with nausea, fullness, or early satiety.

Ilaprazole (10mg gastro-resistant) and Domperidone (30mg prolonged-release) combines a next-generation substituted benzimidazole PPI with a prokinetic antiemetic. Ilaprazole exhibits an extended plasma elimination half-life (~7-8 hours vs 1-2 hours for older PPIs), producing deeper, longer nocturnal gastric acid control and superior intragastric pH > 4 holding time. Domperidone ensures enhanced gastric emptying and lower esophageal sphincter competency. Indicated for nocturnal acid breakthrough, severe erosive esophagitis, and refractory GERD with nausea.